1 2 **AEROSOL GENERATION DURING COUGHING - QUANTITATIVE DEFINITION FOR** AEROSOL GENERATING PROCEDURES: OBSERVATIONAL STUDY PhD, ENNI 3 SANMARK^{1,2}, MD, LOTTA-MARIA A.H. OKSANEN^{1,2}, MSc NOORA RANTANEN^{1,2}, MD 4 MARI LAHELMA^{1,2,3}, Dosent, VELI-JUKKA ANTTILA^{1,4}, Professor, LASSE LEHTONEN^{1,5}, 5 Dosent, ANTTI-PEKKA HYVÄRINEN⁶, Dosent, AHMED GENEID^{1,2} 6 7 ¹ University of Helsinki, Helsinki, Finland Faculty of Medicine 8 ² Helsinki University Hospital, Helsinki, Finland 9 Department of Otorhinolaryngology and Phoniatrics – Head and Neck Surgery 10 3 Faculty of Science, Mathematics and Statistics 11 ⁴ Helsinki University Hospital, Helsinki, Finland 12 HUS Inflammation Center 13 ⁵ Helsinki University Hospital, Helsinki, Finland, HUS Diagnostic Center, HUSLAB 14 ⁶Finnish Meteorological Institute, Helsinki, Finland 15 16 **Corresponding author:** 17 18 Enni Sanmark: 19 Address: Valhallankatu 7a 21, 00250 Helsinki 20 E-mail: enni@sanmark.fi Telephone: +358-408446940 21 ORCID: 0000-0003-0209-5501 22 23 24 25 26 ABSTRACT 27 28 Aim: The purpose of the study was to determine aerosol exposure generated by coughing in 29 operation room environments to create a quantitative limit value for high-risk aerosol-generating 30 medical procedures. 31 Background: Coughing is known to produce a significant amount of aerosols and is thus commonly 32 used as a best reference for high-risk aerosol-generation. Accordingly, procedures during which 33 aerosol generation exceeds the amount of aerosol generated in instances of coughing are seen as 34 high-risk aerosol generating procedures. However, no reliable quantitative values are available for 35 high-risk aerosol-generation.

36	Methods: Coughing was measured from 37 healthy volunteers in the operating room environment.
37	Aerosol particles generated during coughing within the size range of $0.3-10 \mu m$ were measured
38	with Optical Particle Sizer from 40cm, 70cm, and 100cm distances. The distances reflected
39	potential exposure distances where personnel are during surgeries.
40	Results: A total of 306 coughs were measured. Average aerosol concentration during coughing was
41	$1.580 \pm 13.774 \text{ particles/cm}^3 (range 0.000 - 195.528).$
42	Discussion: The aerosol concentration measured in this study can be used as a limit for high-risk
43	aerosol generation in the operating room environment when assessing the aerosol generating
44	procedures and the risk of operating room staff's exposure for aerosol particles.
45 46	ABBREVIATIONS: Aerosol generating procedure (AGP), operating room (OR)
47	RUNNIG TITLE Aerosol generation during coughing
48 49	KEVWORDS Aerosol generating procedure COVID-19 Cough Optical Particle Sizer Aerosol
5 0	KET WORDS Actosol generating procedure, COVID-19, Cough, Optical Farticle Sizer, Actosol
51	
52 52	
55 54	
55	
56	
57	
58	
59	
60 61	
61 62	
62 63	
64	
65	
66	
67	
68	
69	
70	
/1 72	ΙΝΤΡΟΝΙΟΤΙΟΝ
73	

74	Airborne transmission has recently been recognized as an important transmission route of COVID-
75	19 as well as for many other respiratory infections such as tuberculosis and influenza [1-4].
76	Aerosol particles, which can potentially carry pathogens, are generated for example when breathing,
77	talking, and coughing, but also presumably during certain surgical procedures performed in the
78	respiratory tract area where infective pathogens are known to be found. Fear about the spread of
79	COVID-19 during surgeries has led, for example in the field of otorhinolaryngology, to
80	cancellations of surgeries, minimization of staff in the operating room (OR), and changes in
81	personal protective equipment (PPE) guidelines during the current pandemic [5-7].
82	
83	Traditionally, aerosols have been defined as particles smaller than 5um in size that can remain in
8/	the air for long periods of time and spread far into space. However, environmental factors have a
04	the an for long periods of time and spread far into space. However, environmental factors have a
85	significant effect on the dispersion of aerosols and there has been a recent debate regarding whether
86	all particles below 100µm should be considered as aerosols [8, 9]. Overall, aerosol generation is a
87	continuum from the smallest aerosols to larger droplet-sized particles, depending on source.
88	Nonetheless, smaller aerosols are present in higher number and tend to spread the farthest and
89	particles smaller than 5µm have been found to carry the majority of pathogens [10-12]. Findings
90	related to COVID-19 support this assumption: SARS-CoV-2 has been detected in particles 0.25-
91	1.0 μ m, 1–4 μ m, and > 4 μ m. Most results are obtained by PCR, but infectious virus has also been
92	detected in viral culture [13-15]. These facts together make small ($<5 \mu m$) particles most
93	challenging for infection control measures[16].
94	
95	When assessing the risk of infection, the infectious dose associated with the pathogen, the time of
96	exposure and the number of pathogens should be considered. However, both infectious doses of
97	different airborne pathogens and the number of infectious pathogens contained in aerosol particles
98	are yet widely unknown and require further investigation before they can be reliably used as part of

a risk assessment for airborne diseases. Therefore, procedures performed in health care, such as
surgeries, have been classified as potentially aerosol-generating procedures (AGP) or high-risk
AGPs based mainly on the area to be operated and the instruments used, with no degree of
quantification [17, 18].
Coughing is known to produce a potentially infectious amount of aerosols and it has recently been
used as a quantitative reference for high-risk aerosol generation during surgeries and other clinical
procedures [19-21]. It could be said that the current list of aerosol generating procedures is not valid

107 as knowledge of aerosol generation has changed during the pandemic. Many questions persist about

108 quanta and epidemiology in each disease. Procedures in which aerosol generation exceeds the

amount of aerosol concentration produced by coughing are those that could be considered t high-

110 risk aerosol generating procedures (AGP) until further knowledge is obtained [22]. This definition

111 does not take a position on the infectious dose, but together with the exposure time provides an

112 estimate of the potential exposure to airborne pathogens

113 The amount of exposure received by OR staff during the procedure is a key factor in aerosol risk

114 assessment, rather than the total aerosol concentration generated, as highly effective ventilation

115 does lower exposure. Therefore, the purpose of our study was to determine an adequate and

116 quantitative value for high-risk AGPs from the perspective of OR staff by measuring the amount of

117 particle concentration that a person in the OR is exposed to. The results of this study can be applied

118 by comparing the concentration and size distribution of aerosol produced during surgical

119 procedures with the concentration produced by coughing and by estimating the duration of the

120 operation. In the future, as information on infectious doses of various airborne diseases increases,

121 this can be combined with risk assessment.

123 **METHODS** We recruited 37 healthy volunteers to cough in OR and measured the particle 124 generation during coughing. In addition, 15 patients' involuntary cough episodes were measured 125 separately when they woke up from general anesthesia or were under local anesthesia. Coughs 126 during extubations were excluded. We compared volitional and involuntary coughing to ensure that 127 there was no significant difference between these allowing a more accurate quantitative assessment 128 of volitional coughs. All measurements were conducted in the Helsinki University Hospital, 129 between December 2020 and February 2021. The ORs had Recair 4C ventilation system with 130 HEPA-14 filtration, and ultra-clean ventilation in the laminar area of 1210–1298 l/s generating 400 131 - 572,83 air changes per hour. Measurements were performed with the Optical particle sizer (OPS), 132 model TSI model 3330 measuring the size range from 0.3 to 10 μ m and flow rate of 11/min. 133 134 OPS was situated 40 cm, 70 cm, and 100cm from the volunteers to reflect the same distances and 135 thus same particle amounts which OR staff, operating physicians, or assisting nurses are exposed to 136 during surgical operations. Involuntary cough measurements were performed an average of 124 cm 137 (range 40–180 cm) from the patient. No additional collection methods, for example funnels, were 138 used to reflect the actual particle exposure in a certain spot (OR personnels mouth) in the OR 139 environment. Volunteers were asked to cough as hard as possible for three to five times from each 140 distance. Each cough episode was measured separately ensuring that the particles from previous 141 coughs had time to clear from the OR. Coughs were directed towards the OPS device, and particle 142 concentration was measured with a 5- or 10-second scale interval. For each cough, several 143 measurements were collected for 10 seconds. 144 145 The size dependent aerosol concentrations measured with OPS were normalized with respect to the 146 sizing bin widths within 0.3 to 10 μ m. The particle number size distributions and total particle

147 concentrations per cubic centimeter were calculated. The particles were categorized based on the

148	diameter as follows: <1 μ m, 1–5 μ m, and >5 μ m. Due to infection risk being related to cumulative
149	aerosol exposure, the mean was calculated for each patient at each coughing distance as a statistical
150	representative. Pairwise comparisons between voluntary and involuntary coughing were calculated
151	using unpaired Student's t-test with Benjamini-Yekutieli procedure for multiple comparisons with
152	5% false discovery rate[23]. Prior comparisons the data was log10 normalized. The analyses were
153	performed using Microsoft Excel 2016 (Microsoft Corporation, Redmond, Washington, USA), and
154	GraphPad Prism version 9.0.2 for Mac (GraphPad Software, San Diego, California USA) or
155	RStudio version 1.3.959 (R Foundation for Statistical Computing, Vienna, Austria). Measured
156	minimum concentration in all size classes was 0.000. A p-value <0.05 was considered to be
157	statistically significant. STROBE reporting guidelines were followed when preparing the
158	manuscript.
159	
160	All procedures that involved human participants were conducted in accordance with the ethical

standards of the institutional or national research committee and the 1964 Declaration of Helsinki
and its later amendments or comparable ethical standards. The Ethics Committee of Helsinki
University Hospital approved the study protocol (HUS/1701/2020). All participants provided
written informed consent prior to their participation.

165

166**RESULTS AND ANALYSIS** A total of 306 coughs were measured from 37 healthy volunteers.167The detailed information about particle concentrations when coughing from different distances are168presented in **Table 1**. All background concentrations were very low (maximum mean total169concentration 0.0053 particles/cm³) which enabled the accurate evaluation of particle concentration170generated during the procedure. The comparison of involuntary coughs from 15 patients to171volitional coughs are presented in **Figure 1**. Mean particle concentration during involuntary coughs172was 0.140 p/cm³ ± 0.332 (range 0.006–1.308) for particles <1 µm, 0.025 p/cm³ ± 0.068 (range

- 173 0.000–0.270) for particles 1–5 μ m and 0.002 p/cm³ ± 0.006 (range 0.000–0.024) for particles >5
- 174 µm. These measurements were compared with volitional coughs to determine whether the collected
- 175 data also describes involuntary coughing. There were no significant differences between volitional
- and involuntary coughing at any particle size category (p=0.244–0.883).
- 177
- 178 **Table 1.** Observed particle concentration during volitional coughing from different distances

Measured cough episodes, n		All (n=74)	40 cm from source (n=37)	70 cm from source (n=15)	100 cm from source (n=22)
Total particle concentration (particles/cm ³)	Median Mean ±	0.055	0.055	0.026	0.070
(F)	SD	1.706 ± 10.802	0.923 ± 5.078	0.091 ± 0.136	4.12 ± 18.771
	Range	0.000 - 88.157	0.013 - 30.973	0.000 - 0.466	0.016 - 88.157
<1µm particle concentration (particles/cm ³)	Median Mean ±	0.044	0.043	0.026	0.053
	SD	1.692 ± 10.791	0.906 ± 5.030	0.087 ± 0.133	4.111 ± 18.770
	Range	0.000 - 88.141	0.011 - 30.668	0.000 - 0.454	0.011 - 88.141
1–5μm particle concentration (particles/cm ³)	Median Mean ± SD	0.008 0.013 ± 0.035	0.008 0.017 ± 0.049	0.002 0.004 ± 0.004	0.013 0.013 ± 0.006
	Range	0.000 - 0.304	0.000 - 0.304	0.000 - 0.012	0.004 - 0.028
>5µm particle concentration (particles/cm ³)	Median Mean ±	0.000	0.000		0.001
	SD Range	0.001 ± 0.001 0.000 - 0.005	0.001 ± 0.001 0.000 - 0.005	NA	0.001 ± 0.001 0.000 - 0.004

179

180 SD, standard deviation.



Figure 1: Volitional coughing vs. involuntary coughing. (A) Average aerosol size distributions presented with the
background (dotted line) during volitional and anesthesia coughs (involuntary) expressed as mean (line) with 95%
confidence interval (envelopes). (B) Total concentrations and concentrations of <1µm, 1–5µm and >5µm aerosols
during volitional and anesthesia coughs (involuntary), presented as median with interquartile range (box) and range
(whiskers). Volitionally coughing patients, n=37 (coughs n=306); involuntary coughing patients, n=15 (coughs n=15).
c, concentration; Dp, particle diameter; N, particle number

190 **DISCUSSION**

191	In this study we defined a quantitative estimate for high-risk AGP when assessing the risk of
192	exposure of OR staff. By considering the time spent on the OR, as well as the risk of the patient's
193	possible airborne disease, a rough risk assessment of the staff's risk during the procedure was
194	formed. As information on the pathogens contained in aerosol particles as well as infectious doses
195	of airborne diseases increases, these factors can later replace the role of coughing in the risk
196	assessment. Our methodology provides a numeric limit value for the exposure faced by a staff
197	member in an OR environment already considering the environmental factors that affect aerosol
198	dispersion in the space. Thus, the values we measured can be used as a reference when assessing
199	other AGPs that OR staff are exposed to [24].

200 Our results in relation to the aerosol concentration generated by coughing and the role of coughing

as an aerosol generating behaviors (AGBs) are in a line with a recent systematic review. However,

202 we have a higher number of records, we made the systematic distance-dependent evaluation, and 203 we systematically determined aerosol concentrations, which collectively strengthen our study [25]. 204 In our study, the highest aerosol concentrations were observed at 100 cm distance. This is probably 205 due to the methodology: the flow rate of OPS is 11/min. When measuring particles with high 206 acceleration at close range, some particles bypass the device and are not recorded. When distance 207 increases further, the acceleration of the particles is reduced, and they are observed more accurately. 208 However, OPS is currently the most suitable and used measuring device, especially in OR 209 conditions, so when examining the generation of aerosols during surgical procedures its use is 210 justified despite the limitations.

211 The large range and personal differences of the particle concentrations observed in our study is

212 naturally seen in different respiratory activities and related to heterogeneity of the cough[26].

213 However, taking into account similar concentrations of volitional and involuntary coughs, we can

state that the presented data is well representative of the average aerosol concentrations generated

215 during coughing. A previous study of Lee et al. showed that infected patients generated a greater

216 number of particles when coughing compared to the healthy ones[27]. Thus, it could be stated that

the particle concentration seen in our results is the minimum value to determine the limit of AGP.

Whether the definition for AGP is useful at all can be discussed. Understanding humans as aerosol generators during normal respiratory activities has grown and the term aerosol generating behaviors (AGBs) are proposed alongside the AGP [25] However, statistics from around the world show that surgeries involving mucus membranes and respiratory track area were significantly reversed during the COVID-19 pandemic due to the fear of infection. Thus, quantitative variables used for risk assessment are a step forward from previous intuitive measures toward more comprehensive risk assessment.

- 225 **CONCLUSION** This study provides a standard for aerosol concentration and size distribution for
- aerosols generated when coughing to act as reference for high-risk aerosol generation during
- surgical procedures performed in the OR.
- 228 **ACKNOWLEDGMENTS** We thank Catharina Pomoell for her great work as a research nurse.
- 229 CONFLICT OF INTEREST DISCLOSURES: None of the authors has any financial or other
- 230 relationships that might lead to a conflict of interest.
- 231 **INFORMED CONSENT**: All patients provided written informed consent prior to participating in
- the study.
- 233 FUNDING: NA
- 234 ROLES OF AUTHORS BASED ON ICJME STANDARDS: All authors have approved the
- 235 manuscript and have made significant contributions:
- 236 Conceptualization (ES, LMO, VJA, LL); methodology (ES, LMO, APH, VJA, AG); validation (ES,

237 LMO, APH); formal analysis (ES, LOM, NR, ML, APH); investigation (ES, LMO, NR); resources

- 238 (ES, AG); writing original draft (ES); writing review & editing (LMO, NR, ML, APH, LL, VJA,
- AG); visualization (NR, ML); editing (ES); project administration (ES, LMO, AG; VJA); funding
- 240 (ES; APH; AG)
- 241
- 242 243
- 244
- 245
- 246 247
- 248
- 249 250
- 251
- 252
- 253 254
- 255
- 256
- 257

REFERENCES

Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, et al. Tuberculosis.
 Nat Rev Dis Primers. 2016;2:16076. Epub 2016/10/28. doi: 10.1038/nrdp.2016.76. PubMed PMID:
 27784885.

Jones RM, Brosseau LM. Aerosol transmission of infectious disease. J Occup Environ
Med. 2015;57(5):501-8. Epub 2015/03/31. doi: 10.1097/JOM.00000000000448. PubMed PMID:
25816216.

295 3. Cowling BJ, Ip DK, Fang VJ, Suntarattiwong P, Olsen SJ, Levy J, et al. Aerosol
296 transmission is an important mode of influenza A virus spread. Nat Commun. 2013;4:1935. Epub
2013/06/06. doi: 10.1038/ncomms2922. PubMed PMID: 23736803; PubMed Central PMCID:
208 PMCPMC3682670

- 298 PMCPMC3682679.
- Morawska L, Tang JW, Bahnfleth W, Bluyssen PM, Boerstra A, Buonanno G, et al.
 How can airborne transmission of COVID-19 indoors be minimised? Environ Int.
- 301 2020;142:105832. Epub 2020/06/11. doi: 10.1016/j.envint.2020.105832. PubMed PMID:

302 32521345; PubMed Central PMCID: PMCPMC7250761 competing financial interests or personal
 303 relationships that could have appeared to influence the work reported in this paper.

- 304 5. Arman S, Hopkins M, McKean S. The impact of COVID-19 on elective
- 305 otolaryngology surgery in a rural hospital in the United Kingdom. Clin Otolaryngol. 2021. Epub
- 306 2021/06/27. doi: 10.1111/coa.13830. PubMed PMID: 34174165.

307 6. Givi B, Moore MG, Bewley AF, Coffey CS, Cohen MA, Hessel AC, et al. Advanced 308 head and neck surgery training during the COVID-19 pandemic. Head Neck. 2020;42(7):1411-7. 309 Epub 2020/05/10. doi: 10.1002/hed.26252. PubMed PMID: 32383550. 310 Kowalski LP, Sanabria A, Ridge JA, Ng WT, de Bree R, Rinaldo A, et al. COVID-19 7. 311 pandemic: Effects and evidence-based recommendations for otolaryngology and head and neck 312 surgery practice. Head Neck. 2020;42(6):1259-67. Epub 2020/04/10. doi: 10.1002/hed.26164. 313 PubMed PMID: 32270581; PubMed Central PMCID: PMCPMC7262203. 314 8. Vuorinen V, Aarnio M, Alava M, Alopaeus V, Atanasova N, Auvinen M, et al. 315 Modelling aerosol transport and virus exposure with numerical simulations in relation to SARS-316 CoV-2 transmission by inhalation indoors. Saf Sci. 2020;130:104866. Epub 2020/08/25. doi: 317 10.1016/j.ssci.2020.104866. PubMed PMID: 32834511; PubMed Central PMCID: 318 PMCPMC7428778. 319 9. Fernstrom A, Goldblatt M. Aerobiology and its role in the transmission of infectious 320 diseases. J Pathog. 2013;2013:493960. Epub 2013/02/01. doi: 10.1155/2013/493960. PubMed 321 PMID: 23365758; PubMed Central PMCID: PMCPMC3556854. 322 10. Lindsley WG, Blachere FM, Thewlis RE, Vishnu A, Davis KA, Cao G, et al. 323 Measurements of airborne influenza virus in aerosol particles from human coughs. PLoS One. 324 2010;5(11):e15100. Epub 2010/12/15. doi: 10.1371/journal.pone.0015100. PubMed PMID: 325 21152051; PubMed Central PMCID: PMCPMC2994911. 326 Patterson B, Morrow C, Singh V, Moosa A, Gqada M, Woodward J, et al. Detection 11. 327 of Mycobacterium tuberculosis bacilli in bio-aerosols from untreated TB patients. Gates Open Res. 328 2017;1:11. Epub 2018/06/08. doi: 10.12688/gatesopenres.12758.2. PubMed PMID: 29355225; 329 PubMed Central PMCID: PMCPMC5757796. 330 Fennelly KP, Jones-López EC, Ayakaka I, Kim S, Menyha H, Kirenga B, et al. 12. 331 Variability of infectious aerosols produced during coughing by patients with pulmonary 332 tuberculosis. American journal of respiratory and critical care medicine. 2012;186(5):450-7. 333 13. Liu Y, Ning Z, Chen Y, Guo M, Liu Y, Gali NK, et al. Aerodynamic analysis of 334 SARS-CoV-2 in two Wuhan hospitals. Nature. 2020;582(7813):557-60. Epub 2020/04/28. doi: 335 10.1038/s41586-020-2271-3. PubMed PMID: 32340022. 336 14. Chia PY, Coleman KK, Tan YK, Ong SWX, Gum M, Lau SK, et al. Detection of air 337 and surface contamination by SARS-CoV-2 in hospital rooms of infected patients. Nat Commun. 338 2020;11(1):2800. Epub 2020/05/31. doi: 10.1038/s41467-020-16670-2. PubMed PMID: 32472043; 339 PubMed Central PMCID: PMCPMC7260225. 340 Lednicky JA, Lauzardo M, Alam MM, Elbadry MA, Stephenson CJ, Gibson JC, et al. 15. 341 Isolation of SARS-CoV-2 from the air in a car driven by a COVID patient with mild illness. Int J 342 Infect Dis. 2021;108:212-6. Epub 2021/04/27. doi: 10.1016/j.ijid.2021.04.063. PubMed PMID: 343 33901650; PubMed Central PMCID: PMCPMC8064821. 344 Abbey H. An examination of the Reed-Frost theory of epidemics. Human biology. 16. 345 1952;24(3):201. 346 Lagos AE, Ramos PH, Andrade T. Protection for Otolaryngologic Surgery in the 17. 347 COVID-19 Pandemic. OTO Open. 2020;4(2):2473974X20934734. Epub 2020/06/20. doi: 348 10.1177/2473974X20934734. PubMed PMID: 32551408; PubMed Central PMCID: 349 PMCPMC7281886. 350 18. Krajewska J, Krajewski W, Zub K, Zatonski T. COVID-19 in otolaryngologist 351 practice: a review of current knowledge. Eur Arch Otorhinolaryngol. 2020;277(7):1885-97. Epub 352 2020/04/20. doi: 10.1007/s00405-020-05968-y. PubMed PMID: 32306118; PubMed Central 353 PMCID: PMCPMC7166003. 354 Organization WH. 19. 355 Transmission of SARS-CoV-2: implications for infection prevention precautions 2020 [updated 9]

356 July 2020; cited 2020 9 July 2020].

357 20. Brown J, Gregson FKA, Shrimpton A, Cook TM, Bzdek BR, Reid JP, et al. A 358 quantitative evaluation of aerosol generation during tracheal intubation and extubation. 359 Anaesthesia. 2021;76(2):174-81. Epub 2020/10/07. doi: 10.1111/anae.15292. PubMed PMID: 360 33022093; PubMed Central PMCID: PMCPMC7675579. 361 21. Lindsley WG, King WP, Thewlis RE, Reynolds JS, Panday K, Cao G, et al. 362 Dispersion and exposure to a cough-generated aerosol in a simulated medical examination room. J 363 Occup Environ Hyg. 2012;9(12):681-90. Epub 2012/10/05. doi: 10.1080/15459624.2012.725986. 364 PubMed PMID: 23033849; PubMed Central PMCID: PMCPMC4688889. 365 22. Jackson T, Deibert D, Wyatt G, Durand-Moreau Q, Adisesh A, Khunti K, et al. 366 Classification of aerosol-generating procedures: a rapid systematic review. BMJ Open Respir Res. 367 2020;7(1). Epub 2020/10/12. doi: 10.1136/bmjresp-2020-000730. PubMed PMID: 33040021; 368 PubMed Central PMCID: PMCPMC7549490. 369 23. Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing 370 under dependency. Annals of statistics. 2001:1165-88. 371 Prather KA, Marr LC, Schooley RT, McDiarmid MA, Wilson ME, Milton DK. 24. 372 Airborne transmission of SARS-CoV-2. Science. 2020;370(6514):303-4. Epub 2020/10/07. doi: 373 10.1126/science.abf0521. PubMed PMID: 33020250. 374 Chacon AM, Nguyen DD, McCabe P, Madill C. Aerosol-generating behaviours in 25. 375 speech pathology clinical practice: A systematic literature review. PLoS One. 376 2021;16(4):e0250308. Epub 2021/04/29. doi: 10.1371/journal.pone.0250308. PubMed PMID: 377 33909654. 378 26. Mazzone SB, Farrell MJ. Heterogeneity of cough neurobiology: Clinical implications. 379 Pulm Pharmacol Ther. 2019;55:62-6. Epub 2019/02/15. doi: 10.1016/j.pupt.2019.02.002. PubMed 380 PMID: 30763726. 381 27. Jinho Lee DY, Seunghun Ryu, Seunghon Ham, Kiyoung Lee, Myoungsouk Yeo, 382 Kyoungbok Min, Chungsik Yoon Quantity, Size Distribution, and Characteristics of Cough-383 generated Aerosol Produced by Patients with an Upper Respiratory Tract Infection. Aerosol and Air 384 Quality Research. 2019;19(4):840-53. doi: https://doi.org/10.4209/aaqr.2018.01.0031 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402